Home > Organization > Fundamental Innovative Oncology Core > Biomarker and Therapeutic Target Research Core > Department of Biomarkers for Early Detection of Cancer > Research Projects > Practical application of predictive biomarker for adjuvant chemotherapy
Practical application of predictive biomarker for adjuvant chemotherapy
In the reanalysis of the National Cancer Institute Canadian Clinical Trial Group JBR.10, which led to the adoption of adjuvant cisplatin-based chemotherapy for patients with resected stages-IB to IIIA non-small cell lung cancer (NSCLC), we demonstrated a significant clinical benefit of adjuvant chemotherapy for overall survival only in the actinin-4 (ACTN4) high expression group. The data suggested that ACTN4 is a potential predictive biomarker for efficacy of adjuvant chemotherapy in early-stage patients with NSCLC. We are currently preparing a test kit for confirming ACTN4 gene amplification and protein expression with surgical specimens. In the future, we are aiming to develop a diagnostic regent kit in order to improve personalized medicine in adjuvant chemotherapy.